Uniqure N.V. (QURE)

$24.52 -2.13 (-7.99%)
Market Cap 1.66B
Revenue (ttm) 27.12M
Net Income (ttm) -239.56M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -883.33%
Debt to Equity Ratio 0.23
Volume 1,643,300
Avg Vol 2,365,198
Day's Range N/A - N/A
Shares Out 62.29M
Stochastic %K 36%
Beta 0.66
Analysts Strong Sell
Price Target $52.64

Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial t...

Industry: Biotechnology
Sector: Healthcare
Phone: 31 20 240 6000
Address:
Paasheuvelweg 25, Amsterdam, Netherlands
MichaelDV
MichaelDV Feb. 5 at 6:14 PM
$QURE Under the radar, tight range could break big on volume
0 · Reply
Elliord
Elliord Feb. 5 at 5:33 PM
$QURE holding steady, volume confirmation needed to push it higher
0 · Reply
Longbuy1
Longbuy1 Feb. 5 at 5:25 PM
$QURE PR incoming.
0 · Reply
InvestorNOR
InvestorNOR Feb. 5 at 5:22 PM
$QURE Huge news coming tomorrrow! https://x.com/TraderNorway/status/2019453650280534259
0 · Reply
Kiru2020
Kiru2020 Feb. 5 at 4:04 PM
$QURE April $85 call 500x
0 · Reply
smartkarma
smartkarma Feb. 5 at 11:49 AM
$QURE | uniQure Faces FDA Trial Design Challenge Amid Strong Public Support and Regulatory Precedents for AMT-130 Approval "uniQure's AMT-130 for Huntington’s disease showed 75% disease progression slowdown, with positive Phase 1/2 results and NfL biomarker reduction." - Special Situation Investments (Special Situation Investments) Read more: https://www.smartkarma.com/insights/uniqure-faces-fda-trial-design-challenge-amid-strong-public-support-and-regulatory-precedents-for-amt-130-approval
0 · Reply
smartkarma
smartkarma Feb. 5 at 11:45 AM
$QURE | uniQure Faces FDA Trial Design Challenge Amid Strong Public Support and Regulatory Precedents for AMT-130 Approval "uniQure's AMT-130 for Huntington’s disease showed 75% disease progression slowdown, with positive Phase 1/2 results and NfL biomarker reduction." - Special Situation Investments (Special Situation Investments) Read more: https://www.smartkarma.com/insights/uniqure-faces-fda-trial-design-challenge-amid-strong-public-support-and-regulatory-precedents-for-amt-130-approval
0 · Reply
HScottMatusow
HScottMatusow Feb. 5 at 6:33 AM
It's really frustrating for me and @biosleuth to keep reading mostly absurd and scientifically ignorant posts on Uniquire $QURE's AMT-130 and, we don't feel like wasting time writing articles or tweeting on X incessantly about it. https://t.co/alaBqyh54l is our #Discord server - it is free, all you need is a valid email to sign up for Discord (use a throw away if you wish). Everyone can choose to be anonymous there. Danny and I will explain the exact science behind AMT-130, why the Dr. Vinay Prasad wants a better SAP (Bayesian), and why the likeliness of the AA BLA being accepted (based on science and all factors, political, otherwise) and AMT 130 getting approved is high. Once joined, the main chat is https://discord.com/channels/632379593873162278/632379593873162282, and to listen in on the audio feed and interact in chat, Click on broadcast under the "voice channel" on the left to hear audio. $XBI $IBB $QQQ
0 · Reply
Longbuy1
Longbuy1 Feb. 4 at 10:17 PM
$QURE Out of everything you could have shorted, you pick this LMAO.
1 · Reply
JFais
JFais Feb. 4 at 5:00 PM
$REPL wants to hit the ground running in April with RP1 and has ambitious LT expansion plans in place for other solid tumors @stevenvig Key question as always, will the FDA's @DrMakaryFDA and team support innovation or withhold another promising treatment from patients? $QURE
0 · Reply
Latest News on QURE
Alger Small Cap Focus Fund Q4 2025 Portfolio Update

Jan 29, 2026, 1:22 PM EST - 7 days ago

Alger Small Cap Focus Fund Q4 2025 Portfolio Update

EXAS GH NBIS NTRA STVN

uniQure Announces Type A Meeting Scheduled with FDA

Jan 9, 2026, 7:05 AM EST - 27 days ago

uniQure Announces Type A Meeting Scheduled with FDA

uniQure: Now What?

Jan 8, 2026, 3:36 PM EST - 4 weeks ago

uniQure: Now What?

What's Going On With uniQure Stock On Tuesday?

Dec 16, 2025, 12:17 PM EST - 7 weeks ago

What's Going On With uniQure Stock On Tuesday?

Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years

Dec 7, 2025, 12:01 PM EST - 2 months ago

Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years

Why uniQure Stock Is Trading Lower After FDA Meeting Update

Dec 4, 2025, 1:30 PM EST - 2 months ago

Why uniQure Stock Is Trading Lower After FDA Meeting Update

uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease

Dec 4, 2025, 7:05 AM EST - 2 months ago

uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease

Diamond Hill International Strategy Q3 2025 Performance Review

Nov 17, 2025, 8:59 AM EST - 2 months ago

Diamond Hill International Strategy Q3 2025 Performance Review

BABA HDB TSM

uniQure N.V. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - QURE

Nov 14, 2025, 4:17 AM EST - 2 months ago

uniQure N.V. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - QURE

QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with the Schall Law Firm

Nov 12, 2025, 10:00 AM EST - 3 months ago

QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with the Schall Law Firm

From Setback To Surge: UniQure's Huntington's Hope Is Poised For Upside

Nov 10, 2025, 12:44 PM EST - 3 months ago

From Setback To Surge: UniQure's Huntington's Hope Is Poised For Upside

uniQure N.V. (QURE) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 11:11 AM EST - 3 months ago

uniQure N.V. (QURE) Q3 2025 Earnings Call Transcript

uniQure Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 10, 2025, 7:05 AM EST - 3 months ago

uniQure Announces Third Quarter 2025 Financial Results and Provides Corporate Update

uniQure to Announce Third Quarter 2025 Financial Results

Nov 6, 2025, 7:05 AM EST - 3 months ago

uniQure to Announce Third Quarter 2025 Financial Results

UniQure Shares Drop After FDA Shifts Stance On Huntington's Gene Therapy Data

Nov 3, 2025, 1:04 PM EST - 3 months ago

UniQure Shares Drop After FDA Shifts Stance On Huntington's Gene Therapy Data

uniQure N.V. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – QURE

Nov 3, 2025, 10:01 AM EST - 3 months ago

uniQure N.V. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – QURE

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

Nov 3, 2025, 9:58 AM EST - 3 months ago

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

ABBV ALNY AMGN BMY LLY MBX MDGL

UniQure Stock Plummets 67% on Potential FDA Decision. Here's Why.

Nov 3, 2025, 8:11 AM EST - 3 months ago

UniQure Stock Plummets 67% on Potential FDA Decision. Here's Why.

FDA says clinical data for UniQure's Huntington's disease therapy not adequate

Nov 3, 2025, 7:18 AM EST - 3 months ago

FDA says clinical data for UniQure's Huntington's disease therapy not adequate

uniQure: 3-Year Huntington's Data Move AMT-130 From 'Promising' To 'Probable' (Rating Upgrade)

Oct 28, 2025, 1:55 PM EDT - 3 months ago

uniQure: 3-Year Huntington's Data Move AMT-130 From 'Promising' To 'Probable' (Rating Upgrade)

uniQure: Further Upside Likely As The Opportunity Becomes Better Understood

Oct 8, 2025, 3:33 PM EDT - 4 months ago

uniQure: Further Upside Likely As The Opportunity Becomes Better Understood

uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

Sep 29, 2025, 4:05 PM EDT - 4 months ago

uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

uniQure Announces Pricing of Upsized $300 Million Public Offering

Sep 25, 2025, 11:38 PM EDT - 4 months ago

uniQure Announces Pricing of Upsized $300 Million Public Offering

UniQure Stock's 248% Blastoff Was Just The Start — Ask Wall Street

Sep 25, 2025, 8:37 AM EDT - 4 months ago

UniQure Stock's 248% Blastoff Was Just The Start — Ask Wall Street

uniQure Stock Jumps On Positive News, But Risks Remain

Sep 25, 2025, 7:23 AM EDT - 4 months ago

uniQure Stock Jumps On Positive News, But Risks Remain

UniQure: How QURE Stock Rises 10x To $500?

Sep 25, 2025, 6:20 AM EDT - 4 months ago

UniQure: How QURE Stock Rises 10x To $500?

Here's why biotech UniQure's stock just tripled, and brought ClearPoint shares up with it

Sep 24, 2025, 4:37 PM EDT - 4 months ago

Here's why biotech UniQure's stock just tripled, and brought ClearPoint shares up with it

uniQure: Positive 3-Year AMT-130 Data Leads To Pre-BLA FDA Meeting And Beyond

Sep 24, 2025, 4:24 PM EDT - 4 months ago

uniQure: Positive 3-Year AMT-130 Data Leads To Pre-BLA FDA Meeting And Beyond

uniQure Announces $200 Million Proposed Public Offering

Sep 24, 2025, 4:06 PM EDT - 4 months ago

uniQure Announces $200 Million Proposed Public Offering

uniQure N.V. - Special Call

Sep 24, 2025, 1:03 PM EDT - 4 months ago

uniQure N.V. - Special Call

QURE stock skyrockets 200% on ‘three' big news

Sep 24, 2025, 11:20 AM EDT - 4 months ago

QURE stock skyrockets 200% on ‘three' big news

uniQure Stock Doubles On Promising Data From Huntington's Disease Trial

Sep 24, 2025, 10:23 AM EDT - 4 months ago

uniQure Stock Doubles On Promising Data From Huntington's Disease Trial

UniQure's brain disorder drug slows disease progression in trial

Sep 24, 2025, 7:28 AM EDT - 4 months ago

UniQure's brain disorder drug slows disease progression in trial

uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding

Sep 24, 2025, 7:10 AM EDT - 4 months ago

uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding

uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington's Disease

Sep 24, 2025, 7:05 AM EDT - 4 months ago

uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington's Disease

uniQure: Getting Nervous Ahead Of Critical Huntington's Gene Therapy Data

Sep 5, 2025, 4:57 PM EDT - 5 months ago

uniQure: Getting Nervous Ahead Of Critical Huntington's Gene Therapy Data

uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease

Sep 5, 2025, 7:05 AM EDT - 5 months ago

uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

Jul 30, 2025, 11:07 AM EDT - 6 months ago

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

CAPR SRPT CABA NGNE NTLA RCKT

uniQure N.V. (QURE) Q2 2025 Earnings Call Transcript

Jul 29, 2025, 9:07 PM EDT - 6 months ago

uniQure N.V. (QURE) Q2 2025 Earnings Call Transcript

uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress

Jul 29, 2025, 7:05 AM EDT - 6 months ago

uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress

uniQure to Announce Second Quarter 2025 Financial Results

Jul 22, 2025, 7:05 AM EDT - 7 months ago

uniQure to Announce Second Quarter 2025 Financial Results

uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer

Jun 11, 2025, 8:00 AM EDT - 8 months ago

uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer

uniQure's AMT-130 Gene Therapy Warrants An Upgrade

May 28, 2025, 4:56 AM EDT - 9 months ago

uniQure's AMT-130 Gene Therapy Warrants An Upgrade

MichaelDV
MichaelDV Feb. 5 at 6:14 PM
$QURE Under the radar, tight range could break big on volume
0 · Reply
Elliord
Elliord Feb. 5 at 5:33 PM
$QURE holding steady, volume confirmation needed to push it higher
0 · Reply
Longbuy1
Longbuy1 Feb. 5 at 5:25 PM
$QURE PR incoming.
0 · Reply
InvestorNOR
InvestorNOR Feb. 5 at 5:22 PM
$QURE Huge news coming tomorrrow! https://x.com/TraderNorway/status/2019453650280534259
0 · Reply
Kiru2020
Kiru2020 Feb. 5 at 4:04 PM
$QURE April $85 call 500x
0 · Reply
smartkarma
smartkarma Feb. 5 at 11:49 AM
$QURE | uniQure Faces FDA Trial Design Challenge Amid Strong Public Support and Regulatory Precedents for AMT-130 Approval "uniQure's AMT-130 for Huntington’s disease showed 75% disease progression slowdown, with positive Phase 1/2 results and NfL biomarker reduction." - Special Situation Investments (Special Situation Investments) Read more: https://www.smartkarma.com/insights/uniqure-faces-fda-trial-design-challenge-amid-strong-public-support-and-regulatory-precedents-for-amt-130-approval
0 · Reply
smartkarma
smartkarma Feb. 5 at 11:45 AM
$QURE | uniQure Faces FDA Trial Design Challenge Amid Strong Public Support and Regulatory Precedents for AMT-130 Approval "uniQure's AMT-130 for Huntington’s disease showed 75% disease progression slowdown, with positive Phase 1/2 results and NfL biomarker reduction." - Special Situation Investments (Special Situation Investments) Read more: https://www.smartkarma.com/insights/uniqure-faces-fda-trial-design-challenge-amid-strong-public-support-and-regulatory-precedents-for-amt-130-approval
0 · Reply
HScottMatusow
HScottMatusow Feb. 5 at 6:33 AM
It's really frustrating for me and @biosleuth to keep reading mostly absurd and scientifically ignorant posts on Uniquire $QURE's AMT-130 and, we don't feel like wasting time writing articles or tweeting on X incessantly about it. https://t.co/alaBqyh54l is our #Discord server - it is free, all you need is a valid email to sign up for Discord (use a throw away if you wish). Everyone can choose to be anonymous there. Danny and I will explain the exact science behind AMT-130, why the Dr. Vinay Prasad wants a better SAP (Bayesian), and why the likeliness of the AA BLA being accepted (based on science and all factors, political, otherwise) and AMT 130 getting approved is high. Once joined, the main chat is https://discord.com/channels/632379593873162278/632379593873162282, and to listen in on the audio feed and interact in chat, Click on broadcast under the "voice channel" on the left to hear audio. $XBI $IBB $QQQ
0 · Reply
Longbuy1
Longbuy1 Feb. 4 at 10:17 PM
$QURE Out of everything you could have shorted, you pick this LMAO.
1 · Reply
JFais
JFais Feb. 4 at 5:00 PM
$REPL wants to hit the ground running in April with RP1 and has ambitious LT expansion plans in place for other solid tumors @stevenvig Key question as always, will the FDA's @DrMakaryFDA and team support innovation or withhold another promising treatment from patients? $QURE
0 · Reply
Dkll303
Dkll303 Feb. 4 at 3:08 PM
$QURE I like this commentary !! Fitting !
0 · Reply
Dkll303
Dkll303 Feb. 4 at 3:07 PM
$QURE So quiet …all the bagholders are pissed Warned you all, Bogart did too …hahaha
0 · Reply
Dkll303
Dkll303 Feb. 4 at 2:53 PM
$QURE Sam !!! Hit it one more time for the bagholders from yesterday and November 2025 !!!! 🎹🎵🎹🎵🎶🎵🎹🎵🎶🎹🎵🎵🎹
0 · Reply
Dkll303
Dkll303 Feb. 4 at 2:40 PM
$QURE MATT ,,the RAT....fooled you all again ,, yesterday ! His buddies came in and shorted tge shit out of this while looking like a run , hahahaha...
0 · Reply
Dkll303
Dkll303 Feb. 4 at 2:08 PM
$QURE and they GAVE AWAY the HemaB drug to CSL Behring, lol , for 2.5B , pissed that away already , just did 2 offerings , since , cause MATT fcuked up again, and the best part : it costs them more to manufacture it then they get back on royalties !!! That’s an ex stock brokers mentality, “ just get the cash men , fcuk how the stock does, the house needs more cash generated from you losers “
0 · Reply
FillQualityX
FillQualityX Feb. 4 at 1:42 PM
$QURE is a gene therapy company with a lead program for hemophilia B; it faces clinical, regulatory, and commercial risks common to the gene therapy sector, including pricing and delivery challenges.
0 · Reply
Dkll303
Dkll303 Feb. 4 at 11:44 AM
$QURE If you live that long ….hahaha…..they said that in 2020 !!! And it went to $13 !!
0 · Reply
freddie04
freddie04 Feb. 4 at 10:47 AM
$QURE 7490 brokers watching Broker Matt for inside info . The only audience is stock brokers that played with Matt, prior to coming here and playing stock broker again Science ..what the fcuk is that
0 · Reply
freddie04
freddie04 Feb. 3 at 8:41 PM
$QURE Ahhhhh …you’ll see ..early yet with loser Matt
0 · Reply
Longbuy1
Longbuy1 Feb. 3 at 5:59 PM
$QURE never forget these losers.
0 · Reply
stu4
stu4 Feb. 3 at 5:48 PM
$QURE you nailed it !!! More Matt BS…company ran by an ex stock broker ..OH WOW
0 · Reply
MAGA1717
MAGA1717 Feb. 3 at 5:25 PM
$QURE $CLPT 🤡🤡🤡 thx fo yo money asshat…
1 · Reply